Literatur
- 1 Ahlert Th.. Erfahrungsbericht „Aktive Spezifische
Immuntherapie”. an der Universitäts Frauenklinik Heidelberg 1995
- 2
Ahlert Th., Sauerbrei W., Bastert G.. et al. .
Tumor-cell number and viability as quality and efficacy
parameters of autologous virus-modified cancer vaccines in patients with breast
or ovarian cancer.
J Clin Oncol.
1997;
15
1354-1366
- 3
Allison A. C., Byars N. E..
An adjuvant formulation that selectively elicits the
formation of antibodies of protective isotypes and of cell-mediated
immunity.
J Immunol Meth.
1986;
95
157-168
- 4
Alters S. E., Philip R., Philip J. R., Gadea J. R..
Immunotherapy of cancer. Generation of CEA specific CTL
using CEA-peptide pulsed dendritic cells.
Adv Exp Med Biol.
1997;
417
519-524
- 5 Altman Lk.. Who goes first?. Random House, New York 1986: 287
- 6
Apostolopoulos V., McKenzie L. F., Pietersz G. A..
Breast cancer Immunotherapy: current status and future
prospects.
Immunol Cell Biol (Australia).
1996;
74
457-464
- 7
Austin F. C., Boone C. W..
Virus augmentation of the antigenicity of tumor cell
extracts.
Adv cancer Res.
1979;
30
301-345
- 8
Berd jr. D., Maguíre H. C., McCue P.. et al. .
Treatment of metastatic melanoma with an autologous
tumor-cell vaccine: clinical and immunologic results in 64 patients.
J Clin Oncol.
1990;
8
1858-1867
- 9
Bier H., Armonat G., Bier J.. et al. .
Postoperative active-specific immunotherapy of lymph node
micrometastasis in a guineapig tumor model.
Otorhinolaryngology.
1989;
51
197-205
- 10
Chen L., Ashe S., Brady W. A.. et al. .
Costimulation of antitumor immunity by the B7
counterreceptor for the T lymphocyte molecules CD 28 and CTLA-4.
Cell.
1992;
71
- 11
Chen T. T., Tao M. H., Levy R..
Idiotype-cytokine fusion proteins as cancer vaccines.
Relative efficacy of IL-2, IL-4, and granulocyte macrophage colony-stimulating
factor.
J Immunol.
1994;
153
4775-4787
- 12
Cooper P. D., McComb C., Steele E. J..
The adjuvanticity of Algammulin, a new vaccine adjuvant.
Vaccine.
1991;
9
408-415
- 13
Coussens L., Yang-Feng T. L., Chen A. L. E..
Tyrosine kinase receptor with extensive homology to EGF
receptor shares chromosomal location with neu oncogene .
Sience.
1985;
230
1132-1139
- 14
Dillman T. O., Nayak S. K., Beutel L..
Establishing in vitro cultures of autologous tumor cells for
use in active specific immunotherapy.
J Immunother.
1993;
14
65-69
- 14a
Ding L., Lalani E. N., Reddish M.. et al. .
Immunogenicity of synthetic peptides related to the core
peptide sequence endoded by the human Muc-I mucin gene: Effect of immunization
on the growth of murine mammary adenocarcinoma cells transfected with the human
Muc-I gene.
Cancer Immunol Immunother.
1993;
36
9-17
- 15
Disis M. L., Calenoff E., McLaughlin G.. et al. .
Existent T-cell and antibody immunity to HER-2/neu protein
in patients with breast cancer.
Cancer Res.
1994;
54
16-20
- 16
Disis M. L., Gralow J. R., Bernhard H.. et al. .
Peptide-based, but not whole protein, vaccines elicit
immunity to HER-2/neu, an oncogenic self protein.
J Immunol.
1996;
156
3151-3158
- 17 Disis M. L., Cheever M. A., Gralow J. R.. et al. .A phase I study of a HER-2/neu
peptide based vaccine with
GM-CSF as an adjuvant in patients with advanced stage HER-2/neu expressing
cancers. Protocol Nr. 1045.00 The Fred Hutchinson Cancer Research Center Seattle,
USA
- 18
Domagk G..
Die Bedeutung körpereigener Abwehrkräfte für
die Ansiedlung von Geschwulstzellen.
Z Krebsforsch.
1949;
56
247-251
- 19
Evemann J. F., Burnstein T..
Immune enhancement of the tumorigenicity of hamster brain
tumor cells persistently infected with measles virus.
Int J Cancer.
1974;
16
861-869
- 20
Fazely F., Dezube B. J., Allen-Ryan J.. et al. .
Pentoxifylline (Trental) decreases the replication of the
human immunodeficiency virus type 1 in human peripheral blood mononuclear cells
and in cultured T cells.
Blood.
1991;
77
1653-1656
- 21
Forni G., Giovarelli M., Cavallo F.. et al. .
Cytokine-induced tumor immunogenicity from exogenous
cytokines to gene therapy.
J Immunother.
1993;
14
253-257
- 22
Fragerberg J., Hjelm A. L., Ragenhammar P,. et al. .
Tumorregression in monoclonal antibody-treated patients
correlates with the presence of antiidiotype-reactive T lymphocytes.
Cancer Res.
1995;
55
1824-1827
- 23
Freedman R. S., Bowen J. M., Herson J. H.. et al. .
Immunotherapy for vulvar carcinoma with virus-modified
homologous extracts.
Obstet Gynekol.
1983;
62
707-714
- 24
Gabrilovich D. L., Nadaf S., Corak J.. et al. .
Dendritic cells in antitumor immune responses. II. Dendritic
cells grown from bone marrow precursors, but not mature DC from tumor-bearing
mice, are effective antigen carriers in the therapy of established tumors.
Cell Immunol.
1996;
170
111-119
- 25
Garrido F., Ruez-Caballo F., Cabrera T.. et al. .
Implications for immunosurveillance of altered HLA class I
phenotypes in human tumors.
Immunology to day.
1997;
18
89-95
- 26
Hajto T., Hostanska K., Gabius H. J..
Mudulatory potency of the b-galactoside-specific lectin from
mistletoe extract (Iscador) on the host defense in vivo in rabbits and
patients.
Cancer Res.
1989;
49
4803-4808
- 27
Hamburg V. T., Svet-Moldarsky G. J..
Artificial heterogenisation of tumors by means of herpes
simplex and polyoma viruses.
Nature .
1964;
203
772-773
- 28 Hanna jr. M. G., Peters L. C., Hoover jr. H. C.. Immunotherapy by active specific
immunisation.Basic
principles and preclinical studies. In: DeVita, V.T. jr., Hellman, S., Rosenberg,
S.A.
(eds.): Biologic Therapy of Cancer, J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 651-669
- 29
Helling F., Shang A., Calves M.. et al. .
GD3 vaccines for melanoma: Superior
immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Cancer Res.
1994;
54
197-202
- 30
Hellström K. E., Hellström I..
Evidence, that tumor antigens enhance tumor growth in vivo
by interacting with a radiosensitive (suppressor ?) cell population.
Proc Natl Acad Sci USA.
1978;
75
436-440
- 31
Hellström I., Hellström K. E..
Tumor enhancing suppressor activator T-cells in spleens and
thymuses of tumor immune mice.
Proc Natl Acad Sci USA.
1979;
76
5294-5298
- 32 Hellström K. E., Hellström I.. Principles of tumor immunity: Tumor antigens. In:
DeVita, V.T. jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 35-52
- 33 Herr H. W.. Instillation therapy of bladder cancer. In: DeVita, V.T. jr., Hellman,
S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 643-650
- 34 Hersh E. M., Tayler C. W.. Immunotherapy by active immunisation of the host using
non
specific stimulants and immunomodulators. In: DeVita, V.T. jr., Hellman, S.,
Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 613-626
- 35
Hoover H. C., Brandhorst J. S., Peters L. C.. et al. .
Adjuvant active specific immunotherapy for human colorectal
cancer: 6,5-year median follow-up of a phase III prospectively randomized
trial.
J Clin Oncol.
1993;
11
390-399
- 36
Hsu F. J., Caspar C. B., Czerwinski D.. et al. .
Tumor-specific idiotype vaccines in the treatment of
patients with B-cell lymphoma, long-term results of a clinical trial.
Blood .
1997;
89
3129-3135
- 37
Itzkowitz S. H., Yuan M., Montgomery C. K.. et al. .
Expression of Tn, sialosyl-Tn and T-antigens in human colon
cancer.
Cancer Res.
1989;
49
191-204
- 38 Jäger E.. Development of vaccines for treatment of breast cancer. Proc. 6th Int.
Conf. Adjuvant Therapy of Primary Breast Cancer. St.
Gallen Febr/1998: Abstr. S 12
- 39
Kaerre K., Ljunggren H. G., Piontek. et al. .
Selective rejection of H-2-deficient lymphoma variants
suggests alternative immune defence strategy.
Nature.
1986;
319
375-378
- 40
Kall M. A., Hellström I., Hellström K. E..
Different responses of lymphoid cells from tumor-bearing as
compared to tumor-immunized mice when sensitized to tumor specific antigens
in
vitro (Microcytotoxicity assay, suppressor cells).
Proc Natl Acad Sci USA.
1975;
72
50-86
- 41 Kinney A. Y., Sahim A., Vernon S. W.. et al. . The prognostic significance of sialyl-Tn
antigen in women
treated with adjuvant chemotherapy for breast cancer. 9th Int Congr Breast Dis.
Houston TX 1996
- 42
Klein E., Vanky F., Galili U.. et al. .
Separation and characteristics of tumor infiltrating
lymphocytes in man.
. In: Witz, I.P., Hanna, M.G. (eds.): Contemporary Topics
in Immunobiology.
Plenum Press, New York.
1980;
79
- 43
Kobayashi H., Gotohda E., Hosokawa M.. et al. .
Inhibition of metastasis in rats immunized with xenogenized
autologous tumor cells after excision of the primary tumor.
J Natl Cancer Inst.
1975;
54
997-999
- 44 Koprowski H.. Basic aspects of immunotherapy of human tumors. In: Melchers, F.
(ed.): Progress in Immunology
VII. Springer Verlag Berlin 1989: 1087
- 45 Kurzrock R., Gutterman J. U., Talpaz M.. Interferons α β γ: Basic principles and
preclinical studies. In: DeVita, V.T. jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 241-274
- 46 Larson S. M., Cheung Nai-kong V., Leibel S. A.. Antibodies in cancer therapy. Radioisotope
conjugates. In: DeVita, V.T. jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 496-511
- 47
Lee J. H., Klein H. G..
Cellular gene therapy.
Hematol Oncol Clinics North Amer.
1995;
9
91-113
- 48
Lehner B., Schlag P., Liebrich W.. et al. .
Postoperative active specific immunization in curatively
resected colorectal cancer patients with a virus-modified autologous tumor cell
vaccine.
Cancer Immunol Immunother.
1990;
32
173-178
- 49
Lindenmann J., Klein P. A..
Viral oncolysis: increased immunogenicity of host cell
antigen associated with influenza virus.
J Exp Med.
1967;
26
93-108
- 50
Lindenmann J..
Viruses as immunological adjuvants in cancer.
Biochim Biophys Acta.
1974;
355
49-56
- 51
Linsley P. S., Brady W., Grosmaire L..
Binding of the B-cell activation antigen B7 to CD 28
costimulates T-cell proliferation and interleukin-2 mRNA accumulation.
J Exp Med.
1991;
173
721-730
- 52 Livingstone P. O., Oettgen H. F., Old L. J.. Specific active Immunotherapy in cancer
treatment. In: Mihich E (ed); Immunolocial Approaches to Cancer
Therapeutics John Whiley & Sons, New York 1982: 363
- 53
Livingstone P. O., Watanabe T., Shiku H.. et al. .
Serological response of melanoma patients receiving melanoma
cell vaccines.
I.Autologous cultured melanoma cells.
Int J Cancer.
1982;
30
413-418
- 54
Livingstone P. O., Adlusi S., Helling F.. et al. .
Phase I trial of immunological adjuvant QS-21 with a GM2
ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with
malignant melanoma.
Vaccine.
1994;
12
1275-1280
- 55
Livingstone P. O..
Approaches to augmenting the immunogenicity of melanoma
gangliosides: From whole melanoma cells to ganglioside-KLH conjugate
vaccines.
Immunol Rev.
1995;
145
149-166
- 56
Livingstone P., Zhang S., Adlusi S.. et al. .
Tumor cell reactivity mediated by IgM antibodies in sera from
melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is
increased by IgG antibodies.
Cancer Immunol Immunother.
1997;
43
324-330
- 57 Longenecker B. M., Reddisch M., Kogarty R.. et al. .Specificity of the IgG response
in mice and human breast
cancer patients following immunization against synthetic sialyl-Tn, an epitope
with possible functional significance in metastasis. In: Cerian, R.L. (ed.):
Antigen and Antibody Molecular
Engineering in Breast Cancer Diagnosis and Treatment. Plenum Press New York
1994: 105
- 58 Lotze M. T., Rosenberg S. A.. Interleukin-2: Clinical applications. In: DeVita,
V.T. jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 159-177
- 59
Lurquin C., Van Peel A., Mariamé B.. et al. .
Structure of the gene coding for tum- transplantation antigen
P91 A: The mutated exon encodes a peptide recognized with Ld by
cytolytic T-cells.
Cell .
1989;
58
293-303
- 60
MacLean G. D., Bowen-Yacyshyn M. B., Samuel J.. et al. .
Active immunization of human ovarian cancer patients against
a common carcinoma (Thomson-Friedenreich) determinant using a synthetic
carbohydrate antigen.
J Immunother .
1992;
11
292-305
- 61
MacLean G. D., Reddish M. A., Koganty R. R.. et al. .
Immunization of breast cancer patients using a synthetic
syalyl-Tn glycoconjugate plus Detox adjuvant.
Cancer Immunol Immunother.
1993;
36
215-222
- 62
MacLean G. D., Reddish M. A., Koganty R. R.. et al. .
Antibodies against mucin-associated syalyl-Tn-epitopes
correlate with survival of metastatic adenocarcinoma patients undergoing active
specific immunotherapy with synthetic STn vaccine.
J Immunother.
1996;
19
59-67
- 63
MacLean G. D., Miles D. W., Rubens R. D.. et al. .
Enhancing the effect of Theratope STn-KLH cancer vaccine in
patients with metastatic breast cancer by pretreatment with low-dose intravenus
cyclophosphamide.
J Immunother.
1996;
309-316
- 64
Maupas P., Goudeau A., Coursaget P.. et al. .
Immunisation against hepatitis B in man.
Lancet .
1976;
1
1367-1370
- 65
Mellstedt H., Frödin J. E., Basucci G.. et al. .
The therapeutic use of monoclonal antibodies in colorectal
carcinoma.
Semin Oncol.
1991;
18
462-475
- 66
Miles D. W., Towlson K. E., Graham R.. et al. .
A randomised phase II study of sialyl-Tn and Detox B adjuvant
with or without cyclophosphamide pretreatment for the active specific
immunotherapy of breast cancer.
Brit J Cancer.
1996;
74
1292-1296
- 67
Mitchison N. A..
Immunologic approach to cancer.
Transplant Proc.
1970;
11
92-103
- 68
Morcein W., Sundquist B., Höglund S.. et al. .
Iscom a novel structure for antigenic presentation of
membrane proteins from enveloped viruses.
Nature.
1984;
308
457-460
- 69
Nabel G. J., Fox B. A., Post L.. et al. .
A molecular genetic intervention for AIDS - effects of
a transdominant negative form of Rev.
Human Gene Ther.
5;
79-92
- 70
Nepom J. T., Hellström L., Hellström K. E..
Antigen-specific purification of blocking factors from sera
of mice with chemicaly induced tumors.
Proc Natl Acad Sci USA.
1977;
74
4605 -4614
- 71 Oettgen H. F., Od L. J.. The history of cancer immunotherapy. In: DeVita, V.T.
jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 87-119
- 72
Plautz G. E., Yang Z. Y., Wu B. Y.. et al. .
Immunotherapy of malignancy by in vivo gene transfer into
tumors.
Proc Natl Acad Sci USA.
1993;
90
4645-4649
- 73
Price M. R..
Breast-cancer-associated antigens defined by monoclonal
antibodies.
Subcell Biochem.
1988;
12
1-12
- 74
Reisfeld R. A..
Immunochemical characterization of human tumor antigen.
Semin Oncol.
1986;
13
153-164
- 75
Ribi E., Amano K., Cantrell J.. et al. .
Preparation and antitumor activity of nontoxic lipid A.
Cancer Immunol Immunother.
1982;
12
91-96
- 76
Riethmüller G., Schneider-Gädicke E., Schlimok G.. et al. .
Randomised trial of monoclonal antibody for adjuvant therapy
of resected Dukes'C colorectal carcinoma.
Lancet.
1994;
343
1177-1183
- 77
Rosato F. E..
Active specific immunotherapy of human solid tumors.
Ann NY Acad Sci.
1976;
277
332-331
- 78
Rosenberg S. A., Packard B. S., Aebershold P. M.. et al. .
Use of tumor-infiltrating lymphocytes and interleukin-2 in
the immunotherapy of patients with metastatic melanoma. A preliminary
report.
N Engl J Med.
1988;
319
1676
- 79
Schirrmacher V., Heicappell R..
Preventation of metastatic spread by postoperative
immunotherapy with virally modified autologous cells. II Establishment of
specific systemic anti-tumor immunity.
Clin Exp Metast.
1987;
5
147-156
- 80
Schirrmacher V., von Hoegen P..
Importance of tumor cell membrane integrity and viability for
cytotoxyc T-lymphocyte activation by cancer vaccines.
Vaccines Res.
1993;
2
183-196
- 81
Schirrmacher V..
Active specific immunotherapy. A new modality of cancer
treatment involving the patients own immune system.
Onkologie.
1993;
16
290-296
- 82
Schumacher K., Wolf M. F., Ludwig A.. et al. .
Thomsen-Friedenreich antigens, tumor markers with prognostic
value in breast cancer.
Nova Acta Leopoldina NF.
1997;
115-120
- 83
Seigler H. F., Buckley C. F., Sheppard L. B.. et al. .
Adoptive transfer and specific active immunisation of
patients with malignant melanoma.
Ann NY Acad Sci.
1976;
277
522-531
- 84
Shoham J., Hirsch R., Zakay-Rones Z.. et al. .
Augmentation of tumor cell immunogenicity by viruses: an
approach to specific immunotherapy of cancer.
Nat Immun Cell Growth Regul.
1990;
9
165-172
- 85
Sjögren H. O., Hellström K. E., Bansal S. C.. et al. .
Suggestive evidence that the “locking
antibodies” of tumor-bearing individuals may be antigen antibody
complexes.
Proc Natl Acad Sci USA.
1971;
68
1372-1384
- 86
Springer G. F..
T and Tn, general carcinoma autoantigens.
Science.
1984;
224
1198-1206
- 87
Stoeck M., Marland-Noske C., Manasterski M.. et al. .
In vitro expansion and analysis of T lymphocyte
microcultures obtained from the vaccination sites of cancer patients undergoing
active specific immunization with autologous Newcastle-disease-virus-modified
tumor cells.
Cancer Immunol Immunother.
1993;
37
240-244
- 88
Szmuness W., Stevens C. E., Harley E. J.. et al. .
Hepatitis B vaccine. Demonstration of efficacy in a
controlled clinical trial in a high-risk population in the United States.
N Engl J Med.
1980;
303
833-841
- 89
Tao M. H., Levy R..
Idiotype/granulocyte-macrophage colony-stimulating factor
fusion protein as vaccine for B-cell lymphoma.
Nature.
1993;
362
755-758
- 90 Topalian S. L., Rosenberg S. A.. Adoptive cellular therapy: Basic principles. In:
DeVita, V.T. jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 178-196
- 91
Townsend A., Gotsch F., Davey J..
Cytotoxic T cells recognize fragments of the influenza
nucleoprotein.
Cell .
1985;
457-467
- 92
Townsend A., Bastian J., Brownlen G..
Cytotoxic T lymphocytes recognize influenza hemagglutinin
that lacks a signal sequence.
Nature .
1986;
324
575-577
- 93
Townsend A., Rothbard J., Gotch F.. et al. .
.The epitopes of influenza nucleoprotein recognized by
cytotoxic T lymphocytes can be defined with short synthetic peptides.
Cell.
44
959-968
- 94
Townsend S. E., Allison J. P..
Tumor rejection after direct costimulation of CD8 + T Cells
by B7-transfected melanoma cells.
Science .
1993;
259
366-370
- 95 Vitetta E. S., Thorpe P. E.. Antibodies in cancer therapy: Immunotoxins. In: DeVita,
V.T. jr., Hellman, S., Rosenberg, S.A.
(eds.): Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia, New
York, London,
Hagerstown 1991: 482-495
- 96
Wallack M. K..
Specific tumor immunity produced by the injection of vaccinia
viral oncolysates.
J Surg Res.
1982;
33
11-16
- 97
Wallich R., Bulbuc N., Haemmerling G.. et al. .
Abrogation of metastatic properties of tumor cells by de
novo expression of H-2K antigens following H-2 gene transfection.
Nature.
1985;
315
301-305
- 98
Wolf M. F., Ludwig A., Fritz P.. et al. .
Increased expression of Thomsen-Friedenreich antigens during
tumor progression in breast cancer patients.
Tumor Biol.
1988;
9
190-194
- 99
Wolf S. F., Bliss J., van Cleave V.. et al. .
Interleukin 12 (IL-12) as vaccine adjuvant promotes T helper
(Th) cell type 1 (Th1) and suppresses Th cell type 2 (Th2) immune
responses.
Cancer Biother.
1995;
10
81-86
- 100
Yeh M. Y., Hellström I., Hellström K. E..
Clonal variation in expression of a human melanoma antigen
defined by a monoclonal antibody.
J Immunol.
1981;
1312-1318
- 101
Zatloukal K., Schmidt W., Cotten M.. et al. .
Somatic gene therapy for cancer: the utility of
transferinfection in generating tumor vaccines.
Gene.
1993;
135
199-207
- 102
Zhang S., Walberg L. A., Ogata S.. et al. .
Immune sera and monoclonal antibodies define low
configurations for the sialyl Tn tumor antigen.
Cancer Res.
1995;
55
3364-3368
Korrespondenzadresse:
Prof. Dr. Kurt Schumacher
Unterer Schlossberg 13
70839 Gerlingen
